Details for Patent: 8,026,274

Title:	Use of oxandrolone in the treatment of burns and other wounds
Abstract:	The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.
Inventor(s):	Fishbein; Don (Westfield, NJ)
Assignee:	Savient Pharmaceuticals, Inc. (East Brunswick, NJ)
Filing Date:	Mar 12, 2004
Application Number:	10/799,197
Claims:	1. A method of promoting weight gain after weight loss resulting from post-burn catabolism in a patient in need thereof which comprises administering to the patient 10 mg to 100 mg of oxandrolone per day in conjunction with a protein supplement to achieve a daily protein intake by the patient of approximate 2.0 g/kg/day, for a period of three weeks. 2. A method according to claim 1 wherein the amount of oxandrolone administered is about 80 mg per day. 3. A method according to claim 1 wherein the amount of oxandrolone administered is about 20 mg per day. 4. A method according to claim 1 wherein the amount of oxandrolone administered is about 10 mg per day. 5. A method according to claim 1 wherein the oxandrolone is administered orally. 6. A method according to claim 1 wherein the oxandrolone is administered topically. 7. A method according to claim 1 wherein the oxandrolone is administered by injection. 8. A method according to claim 1 wherein the oxandrolone is in a solid dosage form. 9. A method according to claim 1 wherein the oxandrolone is in a liquid dosage form. 10. A method according to claim 1 wherein the oxandrolone is in a sustained-release formulation. 11. A method according to claim 1 wherein the oxandrolone is 17.alpha.-methyl-17.beta.-hydroxy-2-oxa-5.alpha.-androstan-3-one. 12. A method according to claim 1 wherein the weight gain comprises lean body weight gain.